TigaTx

TigaTx is at the forefront of cancer treatment innovation, specializing in the development of engineered IgA antibodies designed to engage neutrophils in the fight against cancer. The company operates in the biotechnology sector, targeting oncology as its primary market. TigaTx serves pharmaceutical companies, healthcare providers, and research institutions that are focused on advanced cancer therapies. The business model revolves around the research and development of proprietary drug candidates, which are then licensed to pharmaceutical companies or brought to market through strategic partnerships. Revenue is generated through licensing fees, milestone payments, and royalties on sales of successfully commercialized drugs. The company is supported by a team of experienced drug developers and a robust scientific advisory board, ensuring a strong foundation for its pioneering work.

Keywords: Engineered IgA, neutrophil engagers, cancer therapy, biotechnology, oncology, drug development, pharmaceutical partnerships, licensing, milestone payments, royalties.